Rituraj Upadhyay1, Bhanu Prasad Venkatesulu2, Prashanth Giridhar3, B K Kim4, Amrish Sharma5, Hagar Elghazawy6, Bhaswanth Dhanireddy7, Thiraviyam Elumalai8, Supriya Mallick3, Matthew Harkenrider9. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address: RUpadhyay@mdanderson.org. 2. Department of Radiation Oncology, Loyola University, Chicago, United States. 3. Department of Radiation Oncology, National Cancer Institute, New Delhi, India. 4. Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston and The University of Texas MD Anderson Cancer Center, Houston, United States. 5. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. 6. Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 7. Radiation Oncology Shawnee Mission, United States. 8. Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 9. Department of Radiation Oncology, Stritch School of Medicine, Loyola University, Maywood, United States.
Abstract
BACKGROUND: Despite the modern advances in treatment techniques, the survival of locally advanced lung cancer patients continues to remain poor. Circulating lymphocytes have an important role to play in local immune response to RT as well as immune checkpoint inhibitors, and radiation related lymphopenia has been associated with inferior survival in various tumors. METHODS: We undertook this systematic review and meta-analysis to evaluate the literature on risk and impact of lymphopenia in thoracic tumors. A systematic methodology search of the PubMed, Embase and Cochrane library was performed and eligible studies selected based on pre-defined inclusion and exclusion criteria. Review Manager Version 5.4.1 was used for the meta-analysis. RESULTS: Fourteen studies were included in the final systematic review and 10 in the quantitative analysis. Overall mean incidence of severe lymphopenia (absolute lymphocyte count < 500) was 64.24%. The patients with severe lymphopenia were at increased risk of death with a pooled HR of 1.59 (95% CI: 1.40, 1.81, I2 = 17%, P < 0.001) and progression with a pooled HR of 2.1 (95% CI: 1.57, 2.81, I2 = 59%, P < 0.001) compared to patients with no severe lymphopenia. Dosimetric parameters including gross tumor volume, lung V5 and heart V5 were predictive of lymphopenia, while advanced age, lower baseline lymphocyte counts, higher stage and large tumor size were other risk factors. Models predicting estimated radiation dose to lymphocytes were a good surrogate for treatment outcomes. CONCLUSION: Radiation related lymphopenia is associated with increased hazard of progression and death in lung cancer. Minimizing the lung and heart dose, especially in patients with concurrent other risk factors can reduce lymphopenia and potentially improve treatment outcomes in these patients.
BACKGROUND: Despite the modern advances in treatment techniques, the survival of locally advanced lung cancerpatients continues to remain poor. Circulating lymphocytes have an important role to play in local immune response to RT as well as immune checkpoint inhibitors, and radiation related lymphopenia has been associated with inferior survival in various tumors. METHODS: We undertook this systematic review and meta-analysis to evaluate the literature on risk and impact of lymphopenia in thoracic tumors. A systematic methodology search of the PubMed, Embase and Cochrane library was performed and eligible studies selected based on pre-defined inclusion and exclusion criteria. Review Manager Version 5.4.1 was used for the meta-analysis. RESULTS: Fourteen studies were included in the final systematic review and 10 in the quantitative analysis. Overall mean incidence of severe lymphopenia (absolute lymphocyte count < 500) was 64.24%. The patients with severe lymphopenia were at increased risk of death with a pooled HR of 1.59 (95% CI: 1.40, 1.81, I2 = 17%, P < 0.001) and progression with a pooled HR of 2.1 (95% CI: 1.57, 2.81, I2 = 59%, P < 0.001) compared to patients with no severe lymphopenia. Dosimetric parameters including gross tumor volume, lung V5 and heart V5 were predictive of lymphopenia, while advanced age, lower baseline lymphocyte counts, higher stage and large tumor size were other risk factors. Models predicting estimated radiation dose to lymphocytes were a good surrogate for treatment outcomes. CONCLUSION: Radiation related lymphopenia is associated with increased hazard of progression and death in lung cancer. Minimizing the lung and heart dose, especially in patients with concurrent other risk factors can reduce lymphopenia and potentially improve treatment outcomes in these patients.
Authors: Brian De; Ethan B Ludmir; Craig A Messick; Matthew C Cagley; Van K Morris; Prajnan Das; Bruce D Minsky; Cullen M Taniguchi; Grace L Smith; Eugene J Koay; Albert C Koong; Radhe Mohan; Emma B Holliday Journal: J Gastrointest Oncol Date: 2021-10
Authors: Cynthia L Bowes; Vivek Naranbhai; Kerri J St Denis; Evan C Lam; Brittany Bertaux; Florence K Keane; Melin J Khandekar; Alejandro B Balazs; John A Iafrate; Justin F Gainor; Henning Willers Journal: Radiother Oncol Date: 2021-11-25 Impact factor: 6.280
Authors: Wang Jing; Ting Xu; Lirong Wu; Pablo B Lopez; Clemens Grassberger; Susannah G Ellsworth; Radhe Mohan; Brian P Hobbs; George R Blumenschein; Janet Tu; Mehmet Altan; Percy Lee; Zhongxing Liao; Steven H Lin Journal: JTO Clin Res Rep Date: 2022-08-07
Authors: Jaehyeon Park; Ji Woon Yea; Se An Oh; Jongmoo Park; Jae Won Park; Jeong Eun Lee Journal: Cancers (Basel) Date: 2022-09-02 Impact factor: 6.575